Lonza is expanding highly potent active pharmaceutical ingredient and antibody-drug conjugate payload-linker manufacturing capacity at its Visp site in Switzerland.
The investment will enhance the company’s drug-linker centre of excellence and add commercial-scale capabilities for complex HPAPI and ADC payload-linker molecules. The expansion will be located within an existing GMP facility and will include additional production and purification capacity, supported by dedicated analytical and process development laboratories.
The new capacity is intended to support the fast-growing ADC market, where pharmaceutical companies are developing more structurally complex payload-linkers requiring specialist synthesis, containment, purification, and quality control. Lonza says the facility is being designed for multipurpose use and scale-out, allowing it to handle a broad range of payload-linker molecules and add further suites as customer demand grows.
Visp’s expansion is closely connected to Lonza’s wider ADC ecosystem, which includes monoclonal antibody manufacture, conjugation, and drug product manufacturing capabilities across Visp and Stein. Additional quality control capacity will also support handling of highly potent payload-linker molecules.
ADCs sit in one of the most technically demanding parts of oncology supply. They combine targeted antibodies with potent cytotoxic payloads, using linker chemistry to control how and where the payload is released. The manufacturing chain spans biologics production, small molecule synthesis, high-containment handling, purification, conjugation, fill-finish, analytical testing, and regulatory documentation.
Each part of that chain brings different constraints. Monoclonal antibody production requires biologics expertise, while payload-linkers demand high-potency chemistry, containment, and complex purification. Conjugation then brings the two together under tightly controlled process conditions. Integrating more of that capability within a connected manufacturing ecosystem can reduce transfer risk, improve schedule control, and give customers a clearer route from development to commercial supply.
The investment also lands as pharmaceutical manufacturing events and suppliers place greater emphasis on contamination control, cold chain logistics, AI-enabled development, and specialist processing capability. The specialist zones being added at CPHI Milan show how clean operations, logistics, labelling, and digital technologies are increasingly being treated as connected parts of pharmaceutical production rather than separate support functions.
HPAPI manufacturing adds another layer of complexity. Highly potent compounds require containment strategies that protect operators, the environment, and product quality. Equipment design, isolators, cleaning validation, occupational exposure limits, waste handling, and analytical methods all shape whether a process can move safely from development to commercial production.
Payload-linker chemistry is becoming more complex as drug developers pursue more selective, stable, and effective ADC designs. That complexity pushes CDMOs to support smaller development batches, process characterisation, and later commercial volumes without forcing customers through repeated technology transfers. Flexible multipurpose capacity is valuable because ADC pipelines can vary widely in chemistry, scale, and clinical demand.
European pharmaceutical manufacturing continues to hold strategic value as biologics and oncology pipelines expand. Drug developers are looking for partners that combine scientific depth with manufacturing reliability, documentation discipline, regulatory experience, analytical robustness, and high-potency operations held within validated controls. Capacity alone is no longer enough.
Visp already has a significant role in complex pharmaceutical manufacturing, and the latest expansion reinforces that position. By linking payload-linker work to antibody manufacture, conjugation, drug product, and quality control, Lonza is strengthening an integrated route for ADC customers moving from clinical development towards commercial supply.
The broader market will test whether capacity can keep pace with scientific demand. ADCs are among the most active areas in oncology development, but their manufacturing requirements are unforgiving. Companies able to provide safe, flexible, and scalable high-potency production will influence how quickly promising therapies can move from clinical progress to routine supply.
